Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
β-Nicotinamide adenine dinucleotide hydrate
54
CHF
CHF 54.00
In stock
CDX-N0222-G0011 gCHF 54.00
CDX-N0222-G0055 gCHF 162.00
CDX-N0222-G01010 gCHF 272.00
| Product Details | |
|---|---|
| Synonyms | β-DPN; β-NAD; Coenzyme 1; Cozymase; DPN; Diphosphopyridine nucleotide; NAD; Nadide; NSC 20272 |
| Product Type | Chemical |
| Properties | |
| Formula | C21H27N7O14P2 . xH2O |
| MW | 663.43 (anhydrous basis) |
| CAS | 53-84-9 |
| RTECS | UU3450000 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to yellow powder. |
| Solubility | Soluble in water. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | BAWFJGJZGIEFAR-OMYDKTABSA-N |
| Smiles | O[C@H]1C(N2C=NC3=C2N=CN=C3N)O[C@H](COP(O)(OP(OC[C@@H]4[C@@H](O)[C@@H](O)[C@@H]([N+]5=CC(C(N)=O)=CC=C5)O4)([O-])=O)=O)[C@H]1O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
NAD+, known more formally as nicotinamide adenine dinucleotide, is a signaling molecule as well as a cofactor or substrate for many enzymes. It acts as an oxidizing agent, accepting electrons from other molecules while being converted to its reduced form, NADH. NAD+ is also essential for the activity of several enzymes, including poly(ADP)-ribose polymerases and cADP-ribose synthases. For example, it is used by some sirtuins to mediate protein deacetylation, producing O-acetyl-ADP-ribose and nicotinamide as well as the deacetylated protein. NAD+ is an important player and factor to research metabolic pathways and pathologies.
Product References
(1) B. Schwer & E. Verdin; Cell Metabolism 7, 104 (2008) (Review) | (2) R.H. Houtkooper, et al.; Endocr. Rev. 31, 194 (2010) (Review) | (3) Y.S. Elhassan, et al.; J. Endocr. Soc. 1, 816 (2017) (Review)